Quetiapine for insomnia in Parkinson disease: results from an open-label trial.

摘要: Quetiapine is an atypical antipsychotic with sedative properties frequently used to treat hallucinations and psychosis in Parkinson disease (PD). The objective of this trial evaluate quetiapine for insomnia nonpsychotic PD patients. Fourteen consecutive patients frequent without psychotic symptoms were treated openly 12 weeks a single evening dose quetiapine. was adjusted according clinical improvement tolerance. severity assessed using the Pittsburgh Sleep Quality Index (PSQI), daytime sleepiness evaluated Epworth Scale (ESS), motor performance section Unified Parkinson's Disease Rating (UPDRS). All evaluations done before 1, 2, 3 months after initiation treatment. Total PSQI basal scores 13.6 +/- 3.7 points. score improved 11 reduced by 3.8 3.9 points end study (P < 0.01). ESS 4.3 mean 31.9 mg/day. No significant change observed scale. Two discontinued due nonserious adverse effects. These results suggest that may be safe effective treatment Double-blind studies will probably confirm these findings.